What is the rationale for early intervention in high-risk smoldering MM?

The Multiple Myeloma Hub spoke with Shaji Kumar, Mayo Clinic, Rochester, US. We asked about the future perspectives for the treatment of patients with high-risk smoldering multiple myeloma (MM).  In this interview, Dr Kumar explored the emerging treatment landscape for high-risk smoldering MM, highlighting a shift from active monitoring to intervention. Kumar discussed the increasing evidence supporting early treatment in patients at high risk of progression to active MM, including data from clinical trials.  This educational resource is independently supported by Johnson & Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.  Hosted on Acast. See acast.com/privacy for more information.